Home › NCT04949087

Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)

Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patient ≥18y.o. of age
* Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been previously diagnosed on radiographs and clinical evaluation.
* Baseline pain level of VAS \>4

Exclusion Criteria:

* Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, post-traumatic arthritis)
* Ipsilateral shoulder surgery within 1 year
* Any glenohumeral joint injection within 3 months
* Allergy to lidocaine
* Known pregnancy
* Workers compensation case regarding shoulder

About the study

The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This study will help elucidate the therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this patient population.

What is being tested

• Glenohumeral Injection (procedure)

Sponsor: Rush University Medical Center · Participants: 200 · Started: Mar 13, 2023

Contact the study team

• Carla M Edwards, PhD · Phone: 312.563.5735

Official record on ClinicalTrials.gov — NCT04949087

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.